EDAP TMS SA Business Summary

EDAP TMS SA (EDAP) is a global leader in robotic energy-based therapies, primarily generating revenue through three business segments: High-Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution. The company's business model is anchored by its flagship Focal One robotic platform, which drives revenue through high-margin capital equipment sales and an accelerating stream of recurring, procedure-based fees from urological treatments. The ESWL division focuses on the manufacturing and servicing of its Sonolith lithotripters for kidney stone treatment, while the Distribution segment markets complementary third-party medical products like lasers and micro-ultrasound systems. EDAP maintains a dominant position in the focal therapy market for localized prostate cancer, competing directly with Siemens Healthineers, Profound Medical Corp (PROF), and Theraclion SA by leveraging proprietary robotic ultrasound technology to offer a non-invasive alternative to radical surgery. The company is led by CEO Ryan Rhodes, a medtech veteran with over 30 years of experience who previously served as CEO of Restoration Robotics and spent 13 years at Intuitive Surgical, where he established the global urology franchise for the da Vinci system. The executive team includes CFO Ken Mobeck, appointed in 2024 to oversee global finance and investor relations, and COO Emmanuel Carré, who manages operational scaling. EDAP’s strategic direction is further guided by a high-pedigree board of directors, recently strengthened by the February 2026 appointment of David Horn, a former Morgan Stanley healthcare investment banking lead. Other notable board members include Chairman Lance Willsey and Joshua H. Levine, the former CEO of Accuray. The company’s institutional backing is highlighted by a significant 20% stake held by Soleus Capital Management, alongside major investors such as Banque Transatlantique SA and Scoggin Management LP.